TOR: Target of Rapamycin
TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the anti-mycotic, rapamycin. Since that time orthologues have been identified in all eukaryotes examined to date, including humans....
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2004
|
| Schriftenreihe: | Current Topics in Microbiology and Immunology
279 |
| Schlagworte: | |
| Online-Zugang: | DE-355 Volltext |
| Zusammenfassung: | TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the anti-mycotic, rapamycin. Since that time orthologues have been identified in all eukaryotes examined to date, including humans. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anabolic and catabolic responses. The significance of understanding the molecular mechanisms which control TOR function has been underscored by Phase 1 clinical trials, showing that rapamycin is not only therapeutically important as an immunosuppressive but is also efficacious in the treatment of solid tumors. Indeed, currently, homologues of rapamycin are in broad-based trials to determine its use in the treatment of other pathological conditions, such as inflammation and restenosis. Given these observations a great deal of attention has been drawn to TOR and its role cellular homoeostasis and human disease. Here we have gathered the leading figures in the field to summarize their own contributions to uncovering TOR function and to speculate where they think the field will be moving in the next few years |
| Beschreibung: | 1 Online-Ressource (X, 364 p) |
| ISBN: | 9783642189302 |
| DOI: | 10.1007/978-3-642-18930-2 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046148587 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642189302 |9 978-3-642-18930-2 | ||
| 024 | 7 | |a 10.1007/978-3-642-18930-2 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-3-642-18930-2 | ||
| 035 | |a (OCoLC)1119114574 | ||
| 035 | |a (DE-599)BVBBV046148587 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.9041 |2 23 | |
| 084 | |a XI 3750 |0 (DE-625)153001:13129 |2 rvk | ||
| 245 | 1 | 0 | |a TOR |b Target of Rapamycin |c edited by George Thomas, David M. Sabatini, Michael N. Hall |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 2004 | |
| 300 | |a 1 Online-Ressource (X, 364 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Current Topics in Microbiology and Immunology |v 279 | |
| 520 | |a TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the anti-mycotic, rapamycin. Since that time orthologues have been identified in all eukaryotes examined to date, including humans. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anabolic and catabolic responses. The significance of understanding the molecular mechanisms which control TOR function has been underscored by Phase 1 clinical trials, showing that rapamycin is not only therapeutically important as an immunosuppressive but is also efficacious in the treatment of solid tumors. Indeed, currently, homologues of rapamycin are in broad-based trials to determine its use in the treatment of other pathological conditions, such as inflammation and restenosis. Given these observations a great deal of attention has been drawn to TOR and its role cellular homoeostasis and human disease. Here we have gathered the leading figures in the field to summarize their own contributions to uncovering TOR function and to speculate where they think the field will be moving in the next few years | ||
| 650 | 4 | |a Medical Microbiology | |
| 650 | 4 | |a Microbiology | |
| 650 | 0 | 7 | |a Sirolimus |0 (DE-588)4458353-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Sirolimus |0 (DE-588)4458353-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Thomas, George |4 edt | |
| 700 | 1 | |a Sabatini, David M. |4 edt | |
| 700 | 1 | |a Hall, Michael N. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642623608 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540005346 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642189319 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-18930-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031528764 | |
| 966 | e | |u https://doi.org/10.1007/978-3-642-18930-2 |l DE-355 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1811034640372203520 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Thomas, George Sabatini, David M. Hall, Michael N. |
| author2_role | edt edt edt |
| author2_variant | g t gt d m s dm dms m n h mn mnh |
| author_facet | Thomas, George Sabatini, David M. Hall, Michael N. |
| building | Verbundindex |
| bvnumber | BV046148587 |
| classification_rvk | XI 3750 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-3-642-18930-2 (OCoLC)1119114574 (DE-599)BVBBV046148587 |
| dewey-full | 616.9041 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9041 |
| dewey-search | 616.9041 |
| dewey-sort | 3616.9041 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-18930-2 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nmm a2200000zcb4500</leader><controlfield tag="001">BV046148587</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642189302</subfield><subfield code="9">978-3-642-18930-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-18930-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-642-18930-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119114574</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046148587</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9041</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 3750</subfield><subfield code="0">(DE-625)153001:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">TOR</subfield><subfield code="b">Target of Rapamycin</subfield><subfield code="c">edited by George Thomas, David M. Sabatini, Michael N. Hall</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 364 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Current Topics in Microbiology and Immunology</subfield><subfield code="v">279</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the anti-mycotic, rapamycin. Since that time orthologues have been identified in all eukaryotes examined to date, including humans. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anabolic and catabolic responses. The significance of understanding the molecular mechanisms which control TOR function has been underscored by Phase 1 clinical trials, showing that rapamycin is not only therapeutically important as an immunosuppressive but is also efficacious in the treatment of solid tumors. Indeed, currently, homologues of rapamycin are in broad-based trials to determine its use in the treatment of other pathological conditions, such as inflammation and restenosis. Given these observations a great deal of attention has been drawn to TOR and its role cellular homoeostasis and human disease. Here we have gathered the leading figures in the field to summarize their own contributions to uncovering TOR function and to speculate where they think the field will be moving in the next few years</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical Microbiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Microbiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Sirolimus</subfield><subfield code="0">(DE-588)4458353-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Sirolimus</subfield><subfield code="0">(DE-588)4458353-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thomas, George</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabatini, David M.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hall, Michael N.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642623608</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540005346</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642189319</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-18930-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031528764</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-18930-2</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046148587 |
| illustrated | Not Illustrated |
| indexdate | 2024-09-24T00:20:22Z |
| institution | BVB |
| isbn | 9783642189302 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031528764 |
| oclc_num | 1119114574 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 364 p) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | Current Topics in Microbiology and Immunology |
| spelling | TOR Target of Rapamycin edited by George Thomas, David M. Sabatini, Michael N. Hall Berlin, Heidelberg Springer Berlin Heidelberg 2004 1 Online-Ressource (X, 364 p) txt rdacontent c rdamedia cr rdacarrier Current Topics in Microbiology and Immunology 279 TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the anti-mycotic, rapamycin. Since that time orthologues have been identified in all eukaryotes examined to date, including humans. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major anabolic and catabolic responses. The significance of understanding the molecular mechanisms which control TOR function has been underscored by Phase 1 clinical trials, showing that rapamycin is not only therapeutically important as an immunosuppressive but is also efficacious in the treatment of solid tumors. Indeed, currently, homologues of rapamycin are in broad-based trials to determine its use in the treatment of other pathological conditions, such as inflammation and restenosis. Given these observations a great deal of attention has been drawn to TOR and its role cellular homoeostasis and human disease. Here we have gathered the leading figures in the field to summarize their own contributions to uncovering TOR function and to speculate where they think the field will be moving in the next few years Medical Microbiology Microbiology Sirolimus (DE-588)4458353-9 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Sirolimus (DE-588)4458353-9 s DE-604 Thomas, George edt Sabatini, David M. edt Hall, Michael N. edt Erscheint auch als Druck-Ausgabe 9783642623608 Erscheint auch als Druck-Ausgabe 9783540005346 Erscheint auch als Druck-Ausgabe 9783642189319 https://doi.org/10.1007/978-3-642-18930-2 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | TOR Target of Rapamycin Medical Microbiology Microbiology Sirolimus (DE-588)4458353-9 gnd |
| subject_GND | (DE-588)4458353-9 (DE-588)4143413-4 |
| title | TOR Target of Rapamycin |
| title_auth | TOR Target of Rapamycin |
| title_exact_search | TOR Target of Rapamycin |
| title_full | TOR Target of Rapamycin edited by George Thomas, David M. Sabatini, Michael N. Hall |
| title_fullStr | TOR Target of Rapamycin edited by George Thomas, David M. Sabatini, Michael N. Hall |
| title_full_unstemmed | TOR Target of Rapamycin edited by George Thomas, David M. Sabatini, Michael N. Hall |
| title_short | TOR |
| title_sort | tor target of rapamycin |
| title_sub | Target of Rapamycin |
| topic | Medical Microbiology Microbiology Sirolimus (DE-588)4458353-9 gnd |
| topic_facet | Medical Microbiology Microbiology Sirolimus Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-642-18930-2 |
| work_keys_str_mv | AT thomasgeorge tortargetofrapamycin AT sabatinidavidm tortargetofrapamycin AT hallmichaeln tortargetofrapamycin |